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REVIEW
In 1977, the birth of the WHO model list of essential drugs
led the organisation to advocate for the principle that some
medicines were more essential than others, pointing out that
many medicines in developing countries were not useful,
whereas others that were did not reach populations at need.
In the past 25 years, 11 revisions of the list have been
published and 156 WHO member states have adopted
medicines lists.1 The list has been much debated: the
pharmaceutical industry has attacked it for being too
restrictive, and non-governmental organisations (NGOs)
have been critical, in particular of the scant attention paid to
AIDS. Selection criteria for drugs have evolved, including a
change from an experience-based to an evidence-based
approach. The name has also changed, from essential drugs
lists (EDL) to essential medicines lists (EML).
In 1977, essential medicines were “of utmost importance,
basic, indispensable and necessary for the health and needs
of the population”2 and criteria relating to safety, quality,
efficacy, and total cost were defined.2 By 2002 the following
definition was proposed: “Essential medicines are those that
satisfy the priority health care needs of the population. They
are selected with due regard to public health relevance,
evidence on efficacy and safety, and comparative cost-
effectiveness. Essential medicines are intended to be
available within the context of functioning health systems at
all times in adequate amounts, in the appropriate dosage
forms, with assured quality and adequate information, and
at a price the individual and the community can afford. The
implementation of the concept of essential medicines is
intended to be flexible and adaptable to many different
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situations; exactly which medicines are regarded as
essential remains a national responsibility.”3
In this paper, we review the list’s history, evolution,
application by countries, controversies, and future
challenges.4
History
The 1975 World Health Assembly5 asked WHO to assist
member states in selecting and procuring essential
medicines, assuring good quality and reasonable cost 
(panel 1).2,4,5–18 The first list of 205 items (186 medicines)
was published 2 years later.2 At the 1978 Alma Ata
conference, provision of essential medicines was identified
as one of eight key components of primary health care.6
The 1985 Nairobi conference resulted in the development
of WHO’s revised drug strategy, in which the model list
was recognised as important mainly for public sectors; the
emphasis was moved beyond selection of drugs to their
procurement, distribution, rational use, and quality
assurance.9 In 1991, membership of the WHO Expert
Committee on the Use of Essential Drugs was balanced by
including “professionals in essential drugs programmes in
developing countries”4 and by providing comparative cost
information.4 During this period, many countries and
NGOs adopted the essential medicines approach,10 and
the UN emergency health kit included 55 of the list
medicines.
When the 1999 expert committee met to revise the
model list, they expressed concern at the lack of evidence
provided to justify revisions and asked that “a summary of
the appropriate evidence be presented for review”.12
Around this time, the effect of the World Trade
Organization (WTO) trade-related aspects of intellectual
property rights (TRIPS) agreement on access to medicines
was being debated by NGOs, the pharmaceutical industry,
and governments.13 In a WHO discussion document
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The first WHO essential drugs list, published in 1977, was described as a peaceful revolution in international public health.
The list helped to establish the principle that some medicines were more useful than others and that essential medicines
were often inaccessible to many populations. Since then, the essential medicines list (EML) has increased in size; defining
an essential medicine has moved from an experience to an evidence-based process, including criteria such as public-
health relevance, efficacy, safety, and cost-effectiveness. High priced medicines such as antiretrovirals are now included.
Differences exist between the WHO model EML and national EMLs since countries face varying challenges relating to
costs, drug effectiveness, morbidity patterns, and rationality of prescribing. Ensuring equitable access to and rational use
of essential medicines has been promoted through WHO’s revised drug strategy. This approach has required an
engagement by WHO on issues such as the effect of international trade agreements on access to essential medicines and
research and development to ensure availability of new essential medicines.
Search strategy
We did comprehensive literature searches using Medline and
EMBASE. Emphasis was placed on articles published from
1975–2002 containing information on the implementation,
use, effect, and relevance of essential drug lists in developing
countries.
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published in May, 2001,14 an evidence-based transparent
process for revising the list was proposed. This document
was generally well received by member states, with the
exception of the USA, which attacked every aspect of the
list in a detailed memorandum.15 Areas of dispute included
the applicability of the list to developed countries and cost
considerations. After detailed rebuttals, the final revised
procedure was adopted by the WHO Executive Board in
January, 2002.16 In April that year, a meeting of the expert
committee was held under the new procedures, and several
patented antiretrovirals were added to the list.17
Evolution of the EML
The structure of the WHO model EML has remained
largely unchanged since first published; medicines are
divided into two categories: core, defined as efficacious,
safe, and cost-effective medicines for priority conditions
(selected on the basis of current and estimated future
public-health relevance and potential for safe and cost-
effective treatment); and complementary, defined as
“medicines for priority diseases which are efficacious, safe
and cost-effective but not necessarily affordable, or for
which specialized health care facilities or services may be
needed”19.
The process for creating and revising the EML 
(panel 2) has changed substantially. Selection originally
largely involved decisions made by members of the expert
committee, with sometimes little evidence. Before 1991,
inclusion of medicines in the list was mainly a result of
applications from WHO programme staff and the
pharmaceutical industry (Mary Couper, personal
communication). In 2002, an evidence-based approach
was adopted, including public-health relevance, efficacy,
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Panel 1: History of the essential medicines concept
1970: Tanzania made its first EML
1975: Resolution WHA28.66 called on WHO to assist member states to select and procure essential drugs of good quality and at
reasonable cost
1977: First list of 205 items published. WHO criticised for attempting to restrict the right of prescribers to prescribe7
1978: Alma Ata conference identified provision of essential drugs as one of eight key components of primary health care
1981: First edition of Managing Drug Supply identified drug selection as an essential management requirement8
1982: Bangladesh adopted essential drugs list based on the WHO selection and banned 1700 products. World Health Assembly gave
little support to the essential medicines concept
1984: The World Health Assembly resolution known as the Nordic resolution obtained support of all delegations except the USA (West
Germany and Japan abstain)
1985: Nairobi conference brought together NGOs, industry, and government representatives, resulting in the WHO Revised Drug Strategy,
which put emphasis beyond selection on procurement, distribution, rational use, and quality assurance for the public sector
UK introduced a restricted list of medicines
1986: Revised Drugs Strategy received unanimous support by the World Health Assembly
1991: Review of changes in the essential drug list highlighted growth of list and increase in the number of substitutable drugs. Inclusion of
comparative cost information suggested. Many countries and NGOs adopted the essential drugs approach
1997: Second edition of Managing Drug Supply included detailed descriptions on how to select medicines based on prevalent morbidity
patterns and existing standard treatment guidelines11
1999: Concern expressed at lack of evidence provided to justify changes. Change from experience to evidence-based submissions
occupied most of 2000–01
Increasing attention paid to effect of WTO TRIPS agreement. Suggestion made at Seattle WTO meeting that drugs on the WHO essential
drugs list be subject to automatic compulsory licensing to ensure universal access
2001: The WHO discussion document Updating and Disseminating the WHO Model List of Essential Drugs: the Way Forward attacked by
USA in 35-page memorandum. Final version of the revised procedure adopted by the WHO Executive Board in January, 2002 
Doha Declaration stated that the TRIPS agreement should be implemented in a manner “supportive of WTO members’ right to protect
public health and, in particular, to promote access to medicines for all”
2002: Several antiretroviral drugs under patent added to the list. New list published on the internet within days of the meeting;
alphabetical and anatomical therapeutic chemical (ATC) classifications and translations in four languages appeared within months18
WHO developed a web-based Essential Medicines Library.
WHO stated at TRIPS Council meeting that “people of a country which does not have the capacity for domestic production of a needed
product should be no less protected by [TRIPS safeguards than] people who happen to live in countries capable of producing the product.”
Panel 2: The WHO expert committee
A WHO expert committee, appointed by the WHO Director
General, meets to decide which medicines are added or
deleted. The members, ranging between seven and ten in
number, are selected from WHO expert advisory panels; they
are mainly clinical pharmacologists and physicians, although it
is apparent today that pharmacists and public health
professionals should be included. Most members have been
men, although 50% were women in 2002. Despite attempts to
represent all WHO geographic regions, the Western Pacific has
been under-represented with no member present at four expert
committee meetings. The USA is the only country with
consistent representation at all of the expert committee
meetings. The pharmaceutical industry had observer status in
the expert committee meetings until 2001 when the new
procedures were introduced.
Total n medicines* Total F+D Ratio F+D per molecule
Year
1977 186 0 ··
1979 210 250 1·19
1982 216 265 1·23
1984 238 321 1·35
1987 257 375 1·5
1989 267 400 1·5
1991 277 414 1·5
1993 287 431 1·5
1995 286 435 1·52
1997 304 524 1·72
1999 308 547 1·78
2002 320 559 1·72
FD=number of forms plus dosages. *Multiple salt forms of a drug are
counted as two distinct medicines; combination drugs are not counted as
distinct medicines if the single components appear on the EML.
Table 1: Trends in WHO EML
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safety, and cost-effectiveness. However, cost-effectiveness
is considered only within WHO therapeutic categories;
WHO can establish the most cost-effective antimalarials to
add to the list, but cost-effectiveness decisions regarding
treating, say, malaria versus HIV/AIDS, are made at
country level. Information and data used to make
evidence-based decisions are supplied by the Cochrane
Collaboration on request. The EML has nearly doubled in
size from 205 items (186 medicines) in the first edition to
325 (320) in the 12th edition published in 2002; 195
medicines have been added, 86 removed, and 11 have
been reinstated (table 1). Although criticised in the past for
incomplete and non-transparent reasoning behind
revisions, WHO now publishes clear explanations and
evidence for decisions.
Over the past 25 years, some therapeutic classes have
more than tripled in size, including antimigraine drugs,
antidotes and other substances used in poisonings,
antiallergic agents and medicines used in anaphylaxis,
antineoplastics and immunosuppressive medicines used in
palliative care, and disinfectants and antiseptics. Other
therapeutic classes that account for substantial increases
include anaesthetics, analgesics, anti-infectives, and
dermatological medicines.
Some medicines have been added and deleted many
times. Amodiaquine was on the original list, deleted in 1979
because “of its similarity to choloroquine”,20 re-added in
1982 as a suspension on the complementary list, and
removed by name in 1987 “since the square symbol [which
indicates that there are many possible medicines in a
therapeutic class that can be used to treat a given condition]
before chloroquine adequately covers use of this drug”.21 In
1995, the expert committee clarified that the square box
next to chloroquine “is retained solely to accommodate
hydroxychloroquine” (panel 3).22
Relevance of the EML to countries
A cross-sectional analysis of 17 national EMLs, shows that
68% contain fewer than 300 medicines (range 108–389),
compared with 309 on the WHO EML in 1999 (table 2).
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Panel 3: Tension between WHO’s EML and
treatment guidelines
The amodiaquine case illustrates the apparent disconnection
between selection decisions made by WHO expert committees
and those made by WHO experts creating treatment
guidelines. Amodiaquine was deleted from treatment
guidelines by the malaria expert committee in 1990 because
of safety concerns and for lack of apparent advantage over
chloroquine.23 In 1993, however, amodiaquine use was
recommended in cases in which benefits outweighed risks
(WHO 19th Malaria Expert Committee, 1993) and eventually
reinstated in WHO treatment guidelines in 199624 on the basis
of results of a systematic review. Several countries have
followed WHO treatment guideline recommendations, which
has spurred many organisations to request that amodiaquine
be re-added to the WHO model EML. The 2002 Essential
Medicines Expert Committee deferred a decision to add
amodiaquine to the model EML pending evidence on safety
and efficacy in curative treatments. This decision is contrary to
a WHO technical consultation on malaria published in April,
2001, that recommends the use of amodiaquine in areas
where efficacy is high25
Total n Total n Ratio dosage
medicines dosage forms 
on EML† forms to medicines
Country or organisation*
WHO (1999 model EML) 309 547 1·56
Peru 341 423 1·36
Eritrea 325 457 1·4
Karnataka state, India 389 411 1·06
Uganda 317 345 1·09
South Africa 337 422 1·25
Nepal 276 377 1·37
Mongolia 229 374 1·63
Palestine 304 312 1·03
Madagascar 253 389 1·54
Yemen 203 268 1·32
Kazakhstan 335   434 1·3
Kosovo 204 253 1·24
Zimbabwe 196 208 1·06
Burkina Faso 220 239 1·09
Philippines 244 364 1·5
Senegal 176 188 1·07
Republic of Liberia 108 140 1·3
*Countries were non-randomly chosen based on the following criteria: EML was
revised in the past 5 years; EML formatted in same manner as the WHO model
EML; medicines were listed by generic names. An attempt was made to obtain
EMLs from all WHO geographic regions, with at least two countries from every
region, and representation from large and small countries. The country EMLs
were quantitatively and qualitatively compared with one another and with the
1999 WHO model EML. †Duplicates excluded.
Table 2: Cross-sectional analysis of national EMLs
Medicines not Medicines on 1–3 Medicines on Medicines on 
on any national national EMLs 4–6 national 7–8 national
EML EMLs EMLs
Chloroxylenol Amphotericin B Alcuronium Captopril
chloride
Eflornithine Artemether Aluminium Clomipramine
diacetate
Melarsoprol Artesunate Amiloride Coal tar
Nevirapine Benznidazole Azathioprine Glutaral
Oxamniquine Calcium gluconate Calcium folinate Influenza 
vaccine
Pentamidine Chloral hydrate Carbamazepine Levamisole
Pertussis Chloroquine Chloramphenicol Meglumine
vaccine iotroxate
Potassium Cyclophosphamide Chlormethine DL-methionine
iodide
Suramin Diaphragms with Codeine Morphine
spermicide
(nonoxinol)
Diethyltoluamide Daunorubicin Nicotinamide
Ephedrine Desmopressin Sodium nitrite
Epinephrine Dextromethorphan Sodium
nitroprusside
Quinidine Diphtheria vaccine Prazosin
Flucytosine Dithranol Propylthiouracil
Hydrochlorothiazide Doxycycline Quinidine
Imipenem  Ether
cilastatin (anaesthetic)
Iodine Fluorouracil
Levamisole Hydrocortisone
Mefloquine Idoxuridine
Nifurtimox Immunoglobulin
(human normal)
Penicillamine Isoprenaline
Prussian blue Levonorgestrel
(potassium ferric
hexacyanoferrate[II])
Pyrimethamine Mefloquine
Sodium fluoride Meglumine
antimoniate
Sodium thiosulfate Proguanil
Sulfadiazine Propyliodone
Sulfasalazine Pyrantel
Suramin Pyridostigmine
Triclabendazole Riboflavin
Trimethoprim Silver nitrate
Urea Co-trimoxazole 
Valproic acid
Yellow fever 
vaccine
Zidovudine
Table 3: Medicines not on country lists but on WHO model list
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The ratio of dosage forms to medicines ranged from 1·03 to
1·63.
Some differences between WHO and national lists are
expected and justifiable (table 3). Local and regional
morbidity patterns will result in certain medicines, such as
pentamidine and eflornithine, appearing on few national
EMLs. Likewise, medicines newly added to the WHO list,
such as nevirapine and zidovudine, might not be included
on national EMLs because of a time lag. Of especial interest
are medicines such as quinidine and ephedrine that have
been on the WHO list for many years, but have been
deleted from most national EMLs because of lack of use,
new information, or more cost-effective alternatives. Such
medicines probably have no evidence base justifying
inclusion on the WHO list, but will remain until the list is
systematically revised. Similarly, some formulations, such as
reserpine injection, are no longer necessary but have never
been deleted from the model EML. 
The following examples from South Africa and Eritrea
show how two countries—one large and relatively
developed, the other small and underdeveloped—have used
the EML as a key component of their national drug policies
and drug access initiatives. 
South Africa and essential medicines 
South Africa’s experience in many ways mirrors global
challenges. In 1994, the country emerged from decades of
isolation and a political system geared to meet the needs of
an affluent elite. Among the first new health strategies was
the 1996 national drug policy, which was firmly committed
to the use of an essential medicines list.26 Although a limited
list had been used in the public sector from the mid-1980s,
this list had expanded to include some 2600 items. In the
immediate political pre-transition period, the Department
of Pharmacology at the University of Cape Town put
forward a list of around 250 active medicines (350
formulations) organised in four levels of care ranging from
self-medication to medical specialist. 
The South African list was developed by a committee
under intense time pressure, much of it from the political
leadership. The first edition of standard treatment
guidelines and medicines (about 160) for primary health
care was released within 2 months of publication of the
national drug policy. Critics immediately claimed the
committee lacked input from primary-care providers and
was pharmacist-dominated, and that the list was overly
focused on disease rather than on syndromes or presenting
problems.27 After a review process, membership of the
committee was expanded. Although the South African
committees still mainly drew on experience and expert
opinion, they sought first to develop standard treatment
guidelines, from which necessary medicine lists were
extracted. At the end of 1998, a three-volume set of these
lists was released, aimed at primary health care and
paediatric and adult hospital care. 
Although the lists were widely distributed, implemen-
tation was described as patchy and considerable challenges
remained,28 including the apparent dislocation between the
EDL committee and the structures responsible for design of
programmes and training material. The committees were,
in effect, dissolved once the books were published;
maintenance of the lists was therefore neglected, and
guidelines produced by national vertical programmes
increasingly deviated from the selection made by the EDL
committee. A prominent example was the guideline for
postexposure prophylaxis for rape victims, which in addition
to including antiretrovirals suggested the use of
azithromycin;29 the drug is not available in state facilities and
no tender for its procurement has been issued. HIV has
been an issue of great concern in the EDL process.
Although the 1998 list mentions an ideal treatment
approach for HIV and opportunistic infections, it includes a
warning that the medicines are “very costly and cannot be
provided on a mass scale by the public health services . . . it
may only be provided on a limited and selective basis or for
academic and research purposes only”. 
A new committee is being appointed to revise the list,
including people from major programmes such as maternal
and child health, non-communicable diseases, AIDS,
tuberculosis, and mental health. Nominations have also
been sought from provincial pharmacy and therapeutics
committees. There is also commitment to an evidence-
based approach. Furthermore, the new lists will address
allocating prescriber levels, neglected in the 1998 lists,
partly because of time pressures. 
However, country-level EMLs face challenges that the
WHO model list does not—they must result in changes in
the field, save costs, increase rationality of prescribing, and
improve patients’ outcome. Although some baseline data
were collected, follow-up studies are too small to provide
meaningful conclusions. To align procurement processes
with the list is also difficult; around 1600 different
medicines are still procured by the South African public
sector. The increasing use of evidence-based formularies in
the private sector is, however, promising.30
Revising the Eritrean national list of drugs
The first Eritrean national list of drugs was defined in 1993
and contained 305 medicines, the second (in 1996)
contained 315, and the third (2001) contained 325. All
three editions underwent exhaustive review involving most
health professionals in the country. The WHO model list
served as the basis for the first edition, which was produced
by about 30 health professionals. For the second and third
revisions, comments were reviewed at national workshops
attended by more than 100 people, including health
professionals and officials of the Ministry of Health,
professional associations, governmental and international
organisations, and international consultants. Immediately
after its publication, the list gained almost universal
acceptance. The formation of hospital drug and therapeutic
committees and compilation of individual hospital lists of
medicines into a national list assisted this evidence-based
approach and is recommended for future reviews
(Information provided by Embaye Andom, Ministry of
Health, Eritrea).
Implementation and advocacy: the role of NGOs
The first director of the WHO Action Programme on
Essential Drugs described the essential medicines concept
as a peaceful revolution in international public health.
Others characterised the EML as “a brilliant symbolic
strategy on the part of WHO for mobilising opinion and
resources”.31 However, pharmaceutical companies have
consistently opposed the concept. In 1987, the
International Federation of the Pharmaceutical
Manufacturers Associations (IFPMA) called the medical
and economic arguments for the EML fallacious and
claimed that adopting it “could result in sub-optimal
medical care and might reduce health standards”.32 The
pharmaceutical industry was concerned that the EML
would become a global concept applicable to public and
private sectors in developing and developed countries, and
were especially opposed to attempts by developed countries
to introduce limited medicines lists. In 1982, a spokesman
of the US pharmaceutical manufacturers organisation said
“The industry feels strongly that any efforts by the WHO
and national governments to implement this action program
REVIEW
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should not interfere with existing private sector operations”.
The Italian drug industry put it more crudely in response to
the Italian senate’s attempts to introduce an EML, stating
“If they want to turn Italy into a third world country, this is
the way to go about it”.33
The drug industry’s view that EMLs are only for the
public sector of the poorest nations has not changed much
in the past 25 years. The current IFPMA paper about
essential medicines repeats that view and says that policies
extending restrictive drug policies to industrialised countries
pose a serious threat to the delivery of effective health care
and to investment in drug research.32
NGOs have advocated for political support for WHO’s
work on essential medicines and for implementation of
essential medicines policies at the national level (panel 4).
Furthermore, they have a substantial role in the provision of
health care in resource-poor settings, and have used the
EML for the selection and procurement of medicines. The
importance of this approach is perhaps best illustrated by
the chaos and risks posed by inappropriate drug donations;
in Lithuania 11 women went blind as a result of a veterinary
drug, donated by a European NGO, being given mistakenly
for gynaecological problems.34
By the mid-1980s, international agencies including
NGOs such as Médecins Sans Frontières and Oxfam and
professional bodies such as the British Medical Association
and the International Pharmaceutical Federation (FIP) had
adopted essential medicine policies.7 The International
Federation of Red Cross and Red Crescent Societies has a
comprehensive essential medicines policy35 and Médecins
Sans Frontières has an essential medicines guide designed
to address practical field needs.36 In 1998, a group of NGOs
published a guide to encourage NGOs to adopt such
policies for their own operations or as a condition for
funding other groups.37
In 1981, around 50 NGOs met in Geneva to form Health
Action International (HAI) whose aims include  “the safe,
rational and economic use of pharmaceuticals world-wide . .
. and full implementation of the WHO Action programme
on essential drugs.” HAI has been a strong advocate for
EMLS at the national and international level.
However, advocacy for the availability of essential
medicines and removal of non-essential and dangerous
medicines from the market was not sufficient to ensure their
rational use. In 1982, HAI put forward a draft code of
practice that addressed the need for international norms on
promotion, distribution, trade, and technology in the
pharmaceutical sector. Though an international code on the
pharmaceutical sector was never devised, the World Health
Assembly adopted a comprehensive pharmaceutical policy
within the WHO Medicines Strategy in 1986.38 The strategy
has the aim of ensuring equitable access to essential
medicines of acceptable quality, promoting rational use of
medicines, and implementing national medicine policies. In
2001, the WHO Medicines Strategy was expanded to
include a mandate for WHO to work on trade-related issues
affecting the availability of medicines.39
EML and intellectual property 
The AIDS crisis has highlighted the grave inequity in access
to essential medicines and has drawn attention to the
potential consequences of WTO agreements on the
availability of medicines. Most AIDS medicines are fairly
new and are produced in what is effectively a monopoly.
Once the TRIPS agreement is fully implemented (by 2016
for least-developed countries) the cost of all new medicines
worldwide will largely depend on price setting by the patent
holder.
In 1996, an Assembly resolution requested WHO to
“report on the impact of the work of the World Trade
Organization with respect to national drug policies and
essential medicines and make recommendations for
collaboration between WTO and WHO, as appropriate”.40
In 1998, WHO published the first guide containing
recommendations to member states for implementing
TRIPS while restricting the negative effects of increased
patent protection on drug availability.41 At that time,
WHO’s involvement in trade issues was highly
controversial. The emphasis on public health needs versus
trade was seen as a threat in the industrialised world. In
1998, the Directorate General for Trade of the European
Commission concluded, referring to “considerable concern
among the pharmaceutical industry”, “that no priority
should be given to health over intellectual property
considerations”.42 However, subsequent resolutions of the
World Health Assembly have strengthened WHO’s
mandate with respect to trade. In 2001, two resolutions
addressed the need to strengthen policies to increase the
availability of generic medicines and assess the effect of
TRIPS on access to medicines, local manufacturing
capacity, and development of new medicines.43,44
At the 1999 third ministerial conference of WTO in
Seattle, several developing countries proposed adding
medicines on the WHO list to the exceptions to what could
be patented allowed under TRIPS article 27.3(b).45 A
REVIEW
THE LANCET • Vol 361 • May 17, 2003 • www.thelancet.com 1727
Panel 4: NGO influence on the EML
 Since the publication of the first WHO EDL, Acción
Internacional para la Salud (AIS) Bolivia has translated and
distributed the list throughout Bolivia using a network of 
15 volunteer groups. AIS also uses the EML as a basis for
consumer education and campaigning to ensure that
essential medicines remain in production and are available
and affordable
 In Malaysia, the National Poison Centre educates the public
about essential medicines by regularly publishing articles in
the Malaysian newspaper New Strait Times
 In Latvia, the independent drug bulletin Cito! led campaigns
to stop the sales of inessential medicines such as obsolete
antidiarrhoeals and painkillers using the essential
medicines concept
 In 1982, the Dutch parliament adopted a decision that
development aid could be used only to purchase essential
medicines. This action followed a campaign by WEMOS
(Dutch Working Group on Health and Development Issues)
showing that a Dutch company was exporting anabolic
steroids to Bangladesh for use by children to stimulate
growth with development aid
 Since 1988, BUKO (German Federal Congress of
Development Action Groups) Pharma-Kampagne has
published an assessment of the product range of German
pharmaceutical companies to determine whether it
addresses the health needs of people in developing
countries. One of the benchmarks used is the WHO EML.
The latest study on the marketing of German medicines
Poor Choices for Poor Countries, published in 1999, shows
that more than 40% of the medicines sold in developing
countries still do not meet the basic criteria for rational
medicines. However, there are also improvements: 15 years
ago two-thirds of German medicines were rated irrational
 Pakistan Network for Rational Drug Use has successfully
campaigned for the abolition of sales tax on essential
medicines in Pakistan leading to increased affordability 
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counterproposal led by the European Communities was “to
issue . . . compulsory licenses for drugs appearing on the list
of essential drugs of the WHO.”46 But because only around
15 of the 306 products on the WHO list were patented in
certain countries (at the time drugs such as antiretrovirals
were excluded because of cost),47 this proposal would have
greatly limited the scope of compulsory licensing. The
Seattle conference collapsed and no conclusion was
reached.
2001 saw the WTO Doha Declaration on TRIPS and
Public Health, which acknowledged the right of countries to
take measures to protect public health: “. . . while
reiterating our commitments to the TRIPS Agreement, we
affirm that the Agreement can and should be interpreted
and implemented in a manner supportive of WTO
Members’ right to protect public health and, in particular,
to promote access to medicines for all.”48 For this statement
to be of practical use, the issue of the right of countries to
produce generic medicines for export must be adequately
addressed.49
Future perspectives
The 25-year-old essential medicines concept serves as the
basis for the WHO medicines strategy in operation today.50
It has become a global concept used by governments and
health-care providers worldwide.
The development of an evidence-based list within WHO
will be mirrored in countries attempting to implement the
essential medicines concept, which poses major challenges.
Evidence used by WHO to add or remove a drug might
provide some basis for change in country-level decision-
making, but in some cases local trials might also be
necessary. WHO’s web-based Medicines Library will
provide information,51 prices,52 and evidence for decisions, to
assist national committees (figure). Training committee
members in the use of evidence-based medicine resources
might also be necessary.
Another area that national committees could find
challenging is cost-effectiveness analysis. International
measures of effectiveness might be locally applicable and
local costs can be incorporated, but local clinical trials might
be needed to measure effectiveness and international prices
might have to be used for medicines which are not yet
available in the country. Countries might benefit from
international assistance with these issues, as occurred in
Eritrea.
Changes are underway within
WHO to ensure that future EMLs
are evidence based. The Essential
Drugs and Medicines Policy
Department has defined the new
processes, and for the 2002 revision
of the list it provided technical
assistance to specific departments in
developing submissions to the expert
committee. It also supports the
identification of medicines that are
no longer essential and could be
removed. However, the implications
for the clinical or disease control
departments in WHO are profound.
In the past, every department
developed treatment guidelines as an
independent activity. Now, they will
all need to provide evidence that
supports inclusion of the medicines
in their guidelines on the model list.
For example, on May 8, 2002, WHO
announced a new formula for oral
rehydration solution,53 but the 2002 model list that had
been approved the previous month contained the old
formulation; the new formulation was included the
following year. 
Given that the EU and US delegations to the TRIPS
Council considered WHO’s recent advice54 on how to
ensure production and export of generic medicines as
being outside WHO’s mandate, WHO will have to insist
on its duty to advocate for health in future trade debates.
This role includes addressing the issue of the lack of
pharmaceutical research and development for health
needs in developing countries. Only 1% of medicines
developed in the past 25 years have been aimed at these
diseases, despite the substantial burden that they cause.55
The pharmaceutical industry has engaged in several
public-private partnerships, but they are largely still
focused on diseases where there is an economic incentive
(ie, AIDS, malaria, and tuberculosis) and it is too early to
say whether they will be successful. Where will the new
essential medicines for meeting needs specific to
developing countries come from?
Although many people in the world still lack effective
access to essential medicines, the work done by WHO
and its partners has done much to bridge this gap. The
original insight that a restricted list of well chosen
medicines could meet the needs of most of the world
remains as valid now as it did in 1977. However, the
fundamental human right to access to these medicines
remains a challenge and will require further action at the
national and international levels. 
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